1
|
Kholuiskaya SN, Siracusa V, Mukhametova GM, Wasserman LA, Kovalenko VV, Iordanskii AL. An Approach to a Silver Conductive Ink for Inkjet Printer Technology. Polymers (Basel) 2024; 16:1731. [PMID: 38932081 PMCID: PMC11207476 DOI: 10.3390/polym16121731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2024] [Revised: 06/03/2024] [Accepted: 06/10/2024] [Indexed: 06/28/2024] Open
Abstract
Silver-based metal-organic decomposition inks composed of silver salts, complexing agents and volatile solvents are now the subject of much research due to the simplicity and variability of their preparation, their high stability and their relatively low sintering temperature. The use of this type of ink in inkjet printing allows for improved cost-effective and environmentally friendly technology for the production of electrical devices, including flexible electronics. An approach to producing a silver salt-based reactive ink for jet printing has been developed. The test images were printed with an inkjet printer onto polyimide substrates, and two-stage thermal sintering was carried out at temperatures of 60 °C and 100-180 °C. The structure and electrical properties of the obtained conductive lines were investigated. As a result, under optimal conditions an electrically conductive film with low surface resistance of approximately 3 Ω/square can be formed.
Collapse
Affiliation(s)
- Svetlana N. Kholuiskaya
- N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Science (RAS), 4 Kosygina St., 119991 Moscow, Russia; (G.M.M.); (V.V.K.); (A.L.I.)
| | - Valentina Siracusa
- Department of Chemical Science (DSC), University of Catania, Viale A. Doria 6, 95125 Catania, Italy
| | - Gulnaz M. Mukhametova
- N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Science (RAS), 4 Kosygina St., 119991 Moscow, Russia; (G.M.M.); (V.V.K.); (A.L.I.)
| | - Luybov A. Wasserman
- Emanuel Institute of Biochemical Physics, RAS, 4 Kosygina St., 119334 Moscow, Russia;
| | - Vladislav V. Kovalenko
- N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Science (RAS), 4 Kosygina St., 119991 Moscow, Russia; (G.M.M.); (V.V.K.); (A.L.I.)
| | - Alexey L. Iordanskii
- N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Science (RAS), 4 Kosygina St., 119991 Moscow, Russia; (G.M.M.); (V.V.K.); (A.L.I.)
| |
Collapse
|
2
|
Muhindo D, Elkanayati R, Srinivasan P, Repka MA, Ashour EA. Recent Advances in the Applications of Additive Manufacturing (3D Printing) in Drug Delivery: A Comprehensive Review. AAPS PharmSciTech 2023; 24:57. [PMID: 36759435 DOI: 10.1208/s12249-023-02524-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Accepted: 01/26/2023] [Indexed: 02/11/2023] Open
Abstract
There has been a tremendous increase in the investigations of three-dimensional (3D) printing for biomedical and pharmaceutical applications, and drug delivery in particular, ever since the US FDA approved the first 3D printed medicine, SPRITAM® (levetiracetam) in 2015. Three-dimensional printing, also known as additive manufacturing, involves various manufacturing techniques like fused-deposition modeling, 3D inkjet, stereolithography, direct powder extrusion, and selective laser sintering, among other 3D printing techniques, which are based on the digitally controlled layer-by-layer deposition of materials to form various geometries of printlets. In contrast to conventional manufacturing methods, 3D printing technologies provide the unique and important opportunity for the fabrication of personalized dosage forms, which is an important aspect in addressing diverse patient medical needs. There is however the need to speed up the use of 3D printing in the biopharmaceutical industry and clinical settings, and this can be made possible through the integration of modern technologies like artificial intelligence, machine learning, and Internet of Things, into additive manufacturing. This will lead to less human involvement and expertise, independent, streamlined, and intelligent production of personalized medicines. Four-dimensional (4D) printing is another important additive manufacturing technique similar to 3D printing, but adds a 4th dimension defined as time, to the printing. This paper aims to give a detailed review of the applications and principles of operation of various 3D printing technologies in drug delivery, and the materials used in 3D printing, and highlight the challenges and opportunities of additive manufacturing, while introducing the concept of 4D printing and its pharmaceutical applications.
Collapse
Affiliation(s)
- Derick Muhindo
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA
| | - Rasha Elkanayati
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA
| | - Priyanka Srinivasan
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA
| | - Michael A Repka
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.,Pii Center for Pharmaceutical Technology, School of Pharmacy, University of Mississippi, University, MS, 38677, USA
| | - Eman A Ashour
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.
| |
Collapse
|
3
|
Customisable Tablet Printing: The Development of Multimaterial Hot Melt Inkjet 3D Printing to Produce Complex and Personalised Dosage Forms. Pharmaceutics 2021; 13:pharmaceutics13101679. [PMID: 34683972 PMCID: PMC8538252 DOI: 10.3390/pharmaceutics13101679] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Revised: 09/20/2021] [Accepted: 09/27/2021] [Indexed: 12/31/2022] Open
Abstract
One of the most striking characteristics of 3D printing is its capability to produce multi-material objects with complex geometry. In pharmaceutics this translates to the possibility of dosage forms with multi-drug loading, tailored dosing and release. We have developed a novel dual material hot-melt inkjet 3D printing system which allows for precisely controlled multi-material solvent free inkjet printing. This reduces the need for time-consuming exchanges of printable inks and expensive post processing steps. With this printer, we show the potential for design of printed dosage forms for tailored drug release, including single and multi-material complex 3D patterns with defined localised drug loading where a drug-free ink is used as a release-retarding barrier. For this, we used Compritol HD5 ATO (matrix material) and Fenofibrate (model drug) to prepare both drug-free and drug-loaded inks with drug concentrations varying between 5% and 30% (w/w). The printed constructs demonstrated the required physical properties and displayed immediate, extended, delayed and pulsatile drug release depending on drug localisation inside of the printed formulations. For the first time, this paper demonstrates that a commonly used pharmaceutical lipid, Compritol HD5 ATO, can be printed via hot-melt inkjet printing as single ink material, or in combination with a drug, without the need for additional solvents. Concurrently, this paper demonstrates the capabilities of dual material hot-melt inkjet 3D printing system to produce multi-material personalised solid dosage forms.
Collapse
|
4
|
He Y, Abdi M, Trindade GF, Begines B, Dubern J, Prina E, Hook AL, Choong GYH, Ledesma J, Tuck CJ, Rose FRAJ, Hague RJM, Roberts CJ, De Focatiis DSA, Ashcroft IA, Williams P, Irvine DJ, Alexander MR, Wildman RD. Exploiting Generative Design for 3D Printing of Bacterial Biofilm Resistant Composite Devices. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2021; 8:e2100249. [PMID: 34050725 PMCID: PMC8336490 DOI: 10.1002/advs.202100249] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Revised: 04/22/2021] [Indexed: 05/25/2023]
Abstract
As the understanding of disease grows, so does the opportunity for personalization of therapies targeted to the needs of the individual. To bring about a step change in the personalization of medical devices it is shown that multi-material inkjet-based 3D printing can meet this demand by combining functional materials, voxelated manufacturing, and algorithmic design. In this paper composite structures designed with both controlled deformation and reduced biofilm formation are manufactured using two formulations that are deposited selectively and separately. The bacterial biofilm coverage of the resulting composites is reduced by up to 75% compared to commonly used silicone rubbers, without the need for incorporating bioactives. Meanwhile, the composites can be tuned to meet user defined mechanical performance with ±10% deviation. Device manufacture is coupled to finite element modelling and a genetic algorithm that takes the user-specified mechanical deformation and computes the distribution of materials needed to meet this under given load constraints through a generative design process. Manufactured products are assessed against the mechanical and bacterial cell-instructive specifications and illustrate how multifunctional personalization can be achieved using generative design driven multi-material inkjet based 3D printing.
Collapse
Affiliation(s)
- Yinfeng He
- Faculty of EngineeringUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Meisam Abdi
- School of Engineering and Sustainable DevelopmentDe Montfort UniversityLeicesterLE1 9BHUK
| | - Gustavo F. Trindade
- Faculty of EngineeringUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
- Advanced Materials and Healthcare TechnologiesSchool of PharmacyUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Belén Begines
- Department of Organic and Medicinal ChemistrySchool of PharmacyUniversity of SevilleSeville41012Spain
| | - Jean‐Frédéric Dubern
- National Biofilms Innovation CentreUniversity of Nottingham Biodiscovery InstituteSchool of Life SciencesUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Elisabetta Prina
- Advanced Materials and Healthcare TechnologiesSchool of PharmacyUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Andrew L. Hook
- Advanced Materials and Healthcare TechnologiesSchool of PharmacyUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Gabriel Y. H. Choong
- Faculty of EngineeringUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Javier Ledesma
- Faculty of EngineeringUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Christopher J. Tuck
- Faculty of EngineeringUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Felicity R. A. J. Rose
- University of Nottingham Biodiscovery InstituteSchool of PharmacyUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Richard J. M. Hague
- Faculty of EngineeringUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Clive J. Roberts
- Advanced Materials and Healthcare TechnologiesSchool of PharmacyUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | | | - Ian A. Ashcroft
- Faculty of EngineeringUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Paul Williams
- National Biofilms Innovation CentreUniversity of Nottingham Biodiscovery InstituteSchool of Life SciencesUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Derek J. Irvine
- Faculty of EngineeringUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Morgan R. Alexander
- Advanced Materials and Healthcare TechnologiesSchool of PharmacyUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| | - Ricky D. Wildman
- Faculty of EngineeringUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUK
| |
Collapse
|
5
|
Seoane-Viaño I, Trenfield SJ, Basit AW, Goyanes A. Translating 3D printed pharmaceuticals: From hype to real-world clinical applications. Adv Drug Deliv Rev 2021; 174:553-575. [PMID: 33965461 DOI: 10.1016/j.addr.2021.05.003] [Citation(s) in RCA: 129] [Impact Index Per Article: 43.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Revised: 04/04/2021] [Accepted: 05/04/2021] [Indexed: 12/26/2022]
Abstract
Three-dimensional (3D) printing is a revolutionary technology that is disrupting pharmaceutical development by enabling the production of personalised printlets (3D printed drug products) on demand. By creating small batches of dose flexible medicines, this versatile technology offers significant advantages for clinical practice and drug development, namely the ability to personalise medicines to individual patient needs, as well as expedite drug development timelines within preclinical studies through to first-in-human (FIH) and Phase I/II clinical trials. Despite the widely demonstrated benefits of 3D printing pharmaceuticals, the clinical potential of the technology is yet to be realised. In this timely review, we provide an overview of the latest cutting-edge investigations in 3D printing pharmaceuticals in the pre-clinical and clinical arena and offer a forward-looking approach towards strategies to further aid the translation of 3D printing into the clinic.
Collapse
|
6
|
Chou WH, Gamboa A, Morales JO. Inkjet printing of small molecules, biologics, and nanoparticles. Int J Pharm 2021; 600:120462. [PMID: 33711471 DOI: 10.1016/j.ijpharm.2021.120462] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Revised: 03/03/2021] [Accepted: 03/04/2021] [Indexed: 01/02/2023]
Abstract
During the last decades, inkjet printing has emerged as a novel technology and attracted the attention of the pharmaceutical industry, as a potential method for manufacturing personalized and customizable dosage forms to deliver drugs. Commonly, the desired drug is dissolved or dispersed within the ink and then dispensed in various dosage forms. Using this approach, several studies have been conducted to load hydrophilic or poorly water-soluble small molecules onto the surface of different solid substrates, including films, tablets, microneedles, and smart data-enriched edible pharmaceuticals, using two-dimensional and three-dimensional inkjet printing methods, with high dose accuracy and reproducibility. Furthermore, biological drugs, such as peptides, proteins, growth factors, and plasmids, have also been evaluated with positive results, eliciting the expected biological response; nonetheless, minor changes in the structure of these compounds with significant impaired activity cannot be dismissed. Another strategy using inkjet printing is to disperse drug-loaded nanoscale particles in the ink liquid, such as nanosuspension, nanocomplexes, or nanoparticles, which have been explored with promising results. Although these favorable outcomes, the proper selection of ink constituents and the inkjet printer, the correlation of printing cycles and effectively printed doses, the stability studies of drugs within the ink and the optimal analysis of samples before and after the printing process are the main challenges for inkjet printing, and therefore, this review analyzes these aspects to assess the body of current literature and help to guide future investigations on this field.
Collapse
Affiliation(s)
- Wai-Houng Chou
- Department of Pharmaceutical Science and Technology, School of Chemical and Pharmaceutical Sciences, University of Chile, Santiago 8380494, Chile; Advanced Center for Chronic Diseases (ACCDiS), Santiago 8380494, Chile; Center of New Drugs for Hypertension (CENDHY), Santiago 8380494, Chile
| | - Alexander Gamboa
- Department of Pharmaceutical Science and Technology, School of Chemical and Pharmaceutical Sciences, University of Chile, Santiago 8380494, Chile; Centro de Investigación Austral Biotech, Facultad de Ciencias, Universidad Santo Tomás, Avenida Ejército 146, Santiago 8320000, Chile
| | - Javier O Morales
- Department of Pharmaceutical Science and Technology, School of Chemical and Pharmaceutical Sciences, University of Chile, Santiago 8380494, Chile; Advanced Center for Chronic Diseases (ACCDiS), Santiago 8380494, Chile; Center of New Drugs for Hypertension (CENDHY), Santiago 8380494, Chile.
| |
Collapse
|